Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity.
about
Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cellsEnhancement of antinociception by coadministration of minocycline and a non-steroidal anti-inflammatory drug indomethacin in naïve mice and murine models of LPS-induced thermal hyperalgesia and monoarthritisAnti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities.Angiogenesis in rheumatoid arthritis.Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue feverRandomised double-blind trial of combination antibiotic therapy in rheumatoid arthritis.Toll-like receptor mediated modulation of T cell response by commensal intestinal microbiota as a trigger for autoimmune arthritisGut microbiota, immunity, and disease: a complex relationship.Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects.Minocycline: far beyond an antibiotic.A novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline inhibits nociception and oedema in mice.Intestinal Dysbiosis and Rheumatoid Arthritis: A Link between Gut Microbiota and the Pathogenesis of Rheumatoid Arthritis.Rheumatoid arthritis and the role of oral bacteria.Minocycline: Rheumatoid Arthritis.Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitisAntibiotics ameliorate lupus-like symptoms in mice.Evidence of the Immune Relevance of Prevotella copri, a Gut Microbe, in Patients With Rheumatoid Arthritis.Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis.
P2860
Q29614271-36E56AB5-ED85-4ADF-ADA2-3910CB8A9FDFQ33759886-64FBC7C1-7905-4468-9F3E-DE7E0908F99BQ33815397-D4ACFBE3-8CE4-42FD-8114-2014CBCE1F50Q34051829-8C026F2B-FB09-4C22-BDB8-024D0E67A44FQ34726827-7815B913-08D4-4C3F-B51F-ED1C2BF853A9Q35098842-1D64E57F-1135-48E7-850C-F6D983FB8F82Q35157400-644458CD-990A-4C30-A0A4-4D6AE1E425DAQ35195785-D2AF2794-375B-4218-9A10-B1CAF8D39E72Q35840805-E4C54DDD-9AD7-4CCA-AE8E-AE4A3DCBC9FCQ36836358-FB44E3FD-BCD3-4329-8320-FD0883562F71Q36977451-944FFB23-B4A9-4CBD-9111-87CEFDAA7C20Q41692834-9D76264E-2AB2-4F8B-A6A8-39290E599519Q41876321-556E64B3-9670-4B5B-8F3A-615DF03107F9Q42363979-7588867A-1DBA-41C9-A098-FFDB61E4B885Q42369219-C89738E8-DCAB-4D16-9EE0-A003EEB3DFB3Q42653229-AE696AAB-070D-4090-8327-DD2BC0576090Q46457628-C8C07909-A497-459A-BC5C-CB2FA6776148Q47108321-AF622AD9-092B-44F7-9D9A-696FBC71E21B
P2860
Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Should tetracycline treatment ...... reduction in disease activity.
@ast
Should tetracycline treatment ...... reduction in disease activity.
@en
type
label
Should tetracycline treatment ...... reduction in disease activity.
@ast
Should tetracycline treatment ...... reduction in disease activity.
@en
prefLabel
Should tetracycline treatment ...... reduction in disease activity.
@ast
Should tetracycline treatment ...... reduction in disease activity.
@en
P2093
P1476
Should tetracycline treatment ...... reduction in disease activity
@en
P2093
Cesar Pacheco-Tena
Millicent Stone
Paul R Fortin
P304
P407
P577
2003-10-01T00:00:00Z